Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952508 · ClinicalTrials.gov registry record · Phase 2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
A Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Cellectar Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT02952508: Active Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Cellectar Biosciences.
NCT02952508 is a Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Cellectar Biosciences. The registered enrollment target is 120 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02952508, a Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Cellectar Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.
Primary Outcome
Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma
Conditions Studied
Interventions
- DRUG Iopofosine I 131 single dose
- DRUG Iopofosine I 131 multiple dose
- DRUG Iopofosine I 131 fractionated dose
Study Locations (20)
Florida
- Cellectar Biosciences site - Jacksonville
- Cellectar Biosciences site - Miami
- Cellectar Biosciences site - Tampa
New York
- Cellectar Biosciences site - Buffalo
- Cellectar Biosciences site - New York
- Cellectar Biosciences site - Rochester
California
- Cellectar Biosciences site - Los Angeles
- Cellectar Biosciences site - Redlands
Illinois
- Cellectar Biosciences site - Maywood
- Cellectar Biosciences site - Warrenville
Maryland
- Cellectar Biosciences site - Baltimore
- Cellectar Biosciences - Bethesda
District of Columbia
- Cellectar Biosciences site - Washington D.C.
Georgia
- Cellectar Biosciences - Atlanta
Kansas
- Cellectar Biosciences site - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2027-12-22 |
| Phase | Phase 2 |
What the registry record for NCT02952508 still lists
NCT02952508 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower).
The record links to 9 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Iopofosine I 131 single dose is the first listed.
NCT02952508 names 20 study sites across 13 states, led by Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT02952508 about?
NCT02952508 is a clinical study titled "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom". Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL...
What is the current status of trial NCT02952508?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-07-26. Estimated completion is 2027-12-22.
What conditions does trial NCT02952508 study?
This clinical trial studies the following conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT02952508?
The interventions under investigation include: Iopofosine I 131 single dose (DRUG), Iopofosine I 131 multiple dose (DRUG), Iopofosine I 131 fractionated dose (DRUG).
Who is sponsoring clinical trial NCT02952508?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02952508 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02952508's enrollment target sits among peer trials
120 152nd of 438 higher than 284 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI